Primary Sjogren's syndrome and autoimmune cytopenias: a relation often overlooked.
|Abstract:||Primary Sjogren's syndrome is an autoimmune disease wherein there is lymphocytic infiltration of salivary and lacrimal glands. This inflammation is thought to be caused by B-lymphocytes. The most common clinical feature of Sjogren's is dryness of the mouth and eyes, but rare complications can occur such as autoimmune cytopenias. Here we report two cases of immune mediated cytopenias that were diagnosed to be due to Sjogren's syndrome. In both cases, immune suppressive treatment was required.|
|Article Type:||Clinical report|
Autoimmune diseases (Diagnosis)
Autoimmune diseases (Care and treatment)
Sjogren's syndrome (Case studies)
Sjogren's syndrome (Diagnosis)
Sjogren's syndrome (Care and treatment)
|Publication:||Name: Bulletin of the NYU Hospital for Joint Diseases Publisher: J. Michael Ryan Publishing Co. Audience: Academic Format: Magazine/Journal Subject: Health Copyright: COPYRIGHT 2012 J. Michael Ryan Publishing Co. ISSN: 1936-9719|
|Issue:||Date: April, 2012 Source Volume: 70 Source Issue: 2|
|Geographic:||Geographic Scope: United States Geographic Code: 1USA United States|
A 59-year-old female was admitted for symptomatic anemia after presenting to the emergency room with progressively worsening shortness of breath that had developed in the preceding 4 weeks. Her history was significant for hypothyroidism, depression, and hypertension. On admission, her pulse rate was 116 beats per minute, blood pressure was 108/60 mmHg and temperature was 98.5[degrees] F. Her conjunctiva was pale on exam, but there was no evidence of hepatosplenomegaly or lymphadenopathy. Blood work revealed a hemoglobin level of 5.5 g/dL; platelet count was 44/[micro]L, and white cell count was within normal limits. Peripheral smear revealed basophilic stippling, nucleated red blood cells, and absence of schistocytes. Blood work revealed low haptoglobin (< 8 mg/dL), LDH was 778 U/L, retic count was 29.3%, total bilirubin was 2.4 mg/dL, direct Coombs test was positive (warm, polyspecific IgG), and so was the indirect Coombs test. The patient was a Jehovah's Witness and refused transfusion; she was started on solumedrol for a diagnosis of autoimmune hemolytic anemia and immune-mediated thrombocytopenia.
Despite 48 hours of steroids, her hemoglobin and platelet count did not improve, and she was given IVIG, 30 gms daily for a total of 4 days. An autoimmune workup revealed strongly positive Ro or SSA antibody (632 AU/mL, < 99 AU/mL is normal for our lab) and La or SSB antibody (549 AU/mL, < 99 AU/mL is normal for our lab). Rheumatology consult was called. The patient admitted to having a long-standing history of dry mouth and dry eyes. Further serological workup revealed a positive rheumatoid factor 80 IU/mL (< 20 IU/mL is normal), anti-dsDNA and anti-Smith antibodies were negative.
Finally on day 6, despite steroids and IVIG, her hemoglobin and platelet counts did not improve; therefore, a decision to give rituximab was made. She was started on rituximab at a dose of 375 mg/[m.sup.2], given weekly for 4 consecutive weeks. Her hemoglobin level improved after the second infusion, and after the fourth infusion, her hemoglobin level was back to her baseline level (12.3 gm/dL). Similar to hemoglobin improvement, her platelet counts began to rise, and her level was 262/[micro]L upon discharge. The patient continues to be followed up in the outpatient setting, and there has been no recurrence of her anemia or thrombocytopenia.
A previously healthy 26-year-old female was admitted after routine blood work at her primary medicine doctor's office revealed a platelet count of 6/[micro]L. She was diagnosed with hyperthyroidism during her pregnancy several years ago and had been treated with propylthiouracil. She had no significant past medical history except for the history of hyperthyroidism. On enquiring, the patient admitted to having heavy menstrual bleeding the preceding 6 months and easy bruising on her lower extremities for the past 4 weeks. She denied any shortness of breath or fatigue, and systemic review was negative except as stated above. Physical exam failed to reveal hepatosplenomegaly or lymphadenopathy.
Her hemoglobin level was 11.5 g/dL, and platelet count was 11/[micro]L on admission. A peripheral smear revealed basophilic stippling and some tear drop cells. She was started on IVIG for a diagnosis of idiopathic thrombocytopenia (ITP) and concurrently given prednisone at a dose of 1 mg/kg body weight. Her platelet count responded, and within 72 hours, her platelet count was within normal range. Blood work revealed strongly positive ANA (1:1280 titer), both Ro/SSA and La/SSB antibodies were strongly positive (458 AU/mL and 663 AU/mL respectively, normal being < 99 AU/mL for our lab), and rheumatoid factor was positive at 1:1280 IU/ mL. Anti-thyroglobulin antibody (138 IU/mL, normal < 40 IU/mL) and anti-thyroid peroxidase antibodies (341 IU/mL, normal being < 35 IU/mL) were also positive, but her free T4 level was normal. After a 5-day course of IVIG, she was discharged home with her platelet count back to baseline, on 60 mg of prednisone daily with outpatient follow-up. In the outpatient setting, her platelet counts remained stable and a prednisone taper was initiated.
Sjogren's syndrome is among the most common autoimmune disorders, affecting as many as 3 to 4% of the adult population. (1) Primary Sjogren's syndrome (pSS) is a common chronic inflammatory autoimmune disorder associated with B lymphocyte hyper-reactivity. The hallmark of this disease is salivary and lacrimal gland infiltration with lymphocytes and subsequent functional impairment. Most patients have exocrine glands involvement, but the clinical presentation is non-specific and diverse ranging from the common "exocrine disease" manifestation of dry eyes and mouth to the less common non-Hodgkin's lymphoma and autoimmune thyroiditis. (2,3) This varied symptom manifestation results in an average diagnostic delay of 3 to 8 years following the appearance of the first symptoms. (4)
Hematological manifestations are seen in pSS, and leukopenia is the most frequent hematologic abnormality noted in as many as 15% patients with Sjogren's syndrome. (5) Coombs positivity is another common hematologic abnormality in Sjogren's syndrome, noted in 22 to 47% of patients observed in a study by Ramakrishna. (5) There have been a few case reports of pSS associated with AIHA and immune mediated thrombocytopenia. (6,7) The cytopenias may develop before the diagnosis of Sjogren's syndrome, and sicca symptoms may not be the predominant manifestation. (6,8,9) Anemia is another hematological manifestation noted, and the most common type being a mild normocytic anemia of chronic inflammation. Pure red-cell aplasia (PRCA) has also been noted in association with Sjogren's syndrome. (10) Case reports have also associated pSS and agranulocytosis. (11) This could be from either reduced bone marrow neutrophil production, or increased peripheral destruction. (11)
Hematological manifestations are usually asymptomatic; however, serious cytopenias can develop in some cases, necessitating treatment. Treatment generally includes immunosuppressive therapy, and corticosteroids seem to be the mainstay of treatment. However, azathioprine, (6,7) cyclophosphamide, (6) and methotrexate (12) have been used in cases of autoimmune hemolytic anemia, thrombocytopenia, and agranulocytosis associated with Sjogren's syndrome. IVIG in combination with corticosteroids has been tried in agranulocytosis complicating pSS. (11) Plasmapheresis for hemolytic anemia (13) and thrombotic thrombocytopenic purpura (14,15) complicating pSS is reported.
There are studies using hydroxychloroquine and azathioprine in pSS, but none evaluating any improvement in the hematological manifestations of pSS. A study by Price and associates using AZA failed to show any improvement in disease activity variables when measured clinically, serologically, or histologically. (16) Fox and coworkers showed that HCQ use resulted in sustained improvement of local (painful eyes and mouth) as well as systemic manifestations (arthralgias and myalgias) of pSS. (17) However, on literature search, ours is the first case where rituximab was used to treat AIHA associated with pSS with positive results.
Rituximab has been used as an off-label drug in Sjogren's syndrome and especially in lymphoma associated with Sjogren's. In a study from France, where rituximab was used in 16 patients with pSS, it was found to be efficacious for systemic features, such as polysynovitis, cutaneous vasculitis, and it also resulted in regression if not complete remission of associated lymphoma. (18) However, one patient with thrombocytopenia associated with Sjogren's failed to show normalization of platelet counts post rituximab infusion. (18) A phase II study showed that depletion of B cells in patients with pSS (early as well as associated with MALT) led to improvement of subjective and objective parameters of disease activity, including salivary and lacrimal gland function, however, they did not comment on cytopenia. (19)
Rituximab has been used to treat idiopathic thrombocytopenic purpura (ITP) and Evans syndrome, described in several case reports and in small trials, with positive results. (20-22) In a cohort of 25 patients with chronic ITP that were resistant to conventional therapies, weekly rituximab infusion at a dose of 375 mg/[m.sup.2] for 4 weeks showed an overall response rate of 52% with response being sustained for at least 6 months. (23) A systematic review of the safety and efficacy of rituximab in patients with ITP showed that rituximab therapy was associated with mean complete response (platelet count > 150 x [10.sup.9] cells/L) and overall response (platelet count > 50 x [10.sup.9] cells/L) rates of 44 and 63%, respectively. (24)
Based on data available from rituximab's efficacy in autoimmune cytopenias, we can extrapolate that it would be useful in the treatment of cytopenias associated with Sjogren's syndrome.
We describe two cases of primary Sjogren's syndrome with immune mediated anemia and thrombocytopenia. In one of our cases, rituximab was used successfully to treat hemolytic anemia while the other case responded to steroids and IVIG.
The hematological manifestations of pSS are of no clinical significance, but sometimes autoimmune cytopenias can occur, which can be potentially life threatening. Thus, pSS should be considered in the differential diagnosis of all patients who have otherwise inexplicable cytopenias. The occurrence of either high titer RF, hyperglobulinemia or a small monoclonal peak support a possible diagnosis of primary Sjogren's syndrome, which should be actively sought by history, ocular examination, and antibody screening. The physician should always be aware of this association and keep pSS in the differential.
The authors have no financial or proprietary interest in the subject matter or materials discussed, including, but not limited to, employment, consultancies, stock ownership, honoraria, and paid expert testimony.
(1.) Thomas E, Hay EM, Hajeer A, Silman AJ. Sjogren's syndrome: a community-based study of prevalence and impact. Br J Rheumatol. 1998 Oct;37(10):1069-76.
(2.) Asmussen K, Andersen V, Bendixen G, et al. A new model for classification of disease manifestations in primary Sjogren's syndrome: evaluation in a retrospective long-term study. J Intern Med. 1996 Jun;239(6):475-82.
(3.) Oxholm P, Asmussen K. Primary Sjogren's syndrome: the challenge for classification of disease manifestations. J Intern Med. 1996 Jun;239(6):467-74.
(4.) Pavlidis NA, Karsh J, Moutsopoulos HM. The clinical picture of primary Sjogren's syndrome: a retrospective study. J Rheumatol. 1982 Sep-Oct;9(5):685-90.
(5.) Ramakrishna R, Chaudhuri K, Sturgess A, Manoharan A. Haematological manifestations of primary Sjogren's syndrome: a clinicopathological study. Q J Med. 1992 Jul;83(303):547-54.
(6.) Schattner A, Friedman J, Klepfish A, Berrebi A. Immune cytopenias as the presenting finding in primary Sjogren's syndrome. Qjm. 2000 Dec;93(12):825-9.
(7.) Schattner A, Shtalrid M, Berrebi A. Autoimmune hemolytic anemia preceding Sjogren's syndrome. J Rheumatol. 1983 Jun;10(3):482-4.
(8.) Sugai S, Tachibana J, Shimizu S, Konda S. Thrombocytopenia in patients with Sjogren's syndrome. Arthritis Rheum. 1989 Feb;32(2):234-5.
(9.) Kikawada M, Watanabe D, Kimura A, et al. Autoimmune hemolytic anemia in an elderly patient with primary Sjogren's syndrome. Intern Med. 2005 Dec;44(12):1312-5.
(10.) Giordano N, Senesi M, Battisti E, et al. Sjogren's syndrome and pure red cell aplasia. Clin Exp Rheumatol. 1996 MayJun;14(3):344-5.
(11.) Friedman J, Klepfish A, Miller EB, et al. Agranulocytosis in Sjogren's syndrome: two case reports and analysis of 11 additional reported cases. Semin Arthritis Rheum. 2002 Apr;31(5):338-45.
(12.) Coppo P, Sibilia J, Maloisel F, et al. Primary Sjogren's syndrome associated agranulocytosis: a benign disorder? Ann Rheum Dis. 2003 May;62(5):476-8.
(13.) Yamanouchi J, Yokota E, Yamauchi Y, Matsumoto I. [A case of Sjogren's syndrome associated with advanced hemolytic anemia caused by worsening autoimmune cholangiopathy]. Ryumachi. 1998 Aug;38(4):595-9.
(14.) Campbell GN, Gallo JH. Relapsing thrombotic thrombocytopenic purpura (TTP) in Sjogren's syndrome. Aust N Z J Med. 1998 Apr;28(2):214.
(15.) Schattner A, Friedman J, Klepfish A. Thrombotic thrombocytopenic purpura as an initial presentation of primary Sjogren's syndrome. Clin Rheumatol. 2002 Feb;21(1):57-9.
(16.) Price EJ, Rigby SP, Clancy U, Venables PJ. A double blind placebo controlled trial of azathioprine in the treatment of primary Sjogren's syndrome. J Rheumatol. 1998 May;25(5):896-9.
(17.) Fox RI, Dixon R, Guarrasi V, Krubel S. Treatment of primary Sjogren's syndrome with hydroxychloroquine: a retrospective, open-label study. Lupus. 1996 Jun;5 Suppl 1:S31-6.
(18.) Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. Ann Rheum Dis. 2007 Mar;66(3):351-7.
(19.) Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. Arthritis Rheum. 2005 Sept;52(9):2740-50.
(20.) Reddy PS, Deauna-Limayo D, Cook JD, et al. Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura. Ann Hematol. 2005 Apr;84(4):232-5.
(21.) Perrotta AL. Re-treatment of chronic idiopathic thrombocytopenic purpura with rituximab: literature review. Clin Appl Thromb Hemost. 2006 Jan;12(1):97-100.
(22.) Mantadakis E, Danilatou V, Stiakaki E, Kalmanti M. Ritux imab for refractory Evans syndrome and other immunemediated hematologic diseases. Am J Hematol. 2004 Nov;77(3):303-10.
(23.) Stasi R, Pagano A, Stipa E, Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood. 2001 Aug 15;98(4):952-7.
(24.) Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007 Jan 2;146(1):25-33.
Saakshi Khattri, M.D., and Peter Barland, M.D., are in the Division of Rheumatology, Albert Einstein College of Medicine, Bronx, New York.
Khattri S, Barland P. Primary Sjogren's syndrome and autoimmune cytopenias: a relation often overlooked. Bull NYU Hosp Jt Dis. 2012;70(2):130-2.
Correspondence: Saakshi Khattri, M.D., Division of Rheumatology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Bronx, New York 10461; email@example.com.
|Gale Copyright:||Copyright 2012 Gale, Cengage Learning. All rights reserved.|